Etretinate is a second-generation retinoid that was used as an active pharmaceutical ingredient in medications for severe psoriasis. It was developed by Hoffmann–La Roche and approved by the FDA in 1986, but later withdrawn from several markets due to a high risk of birth defects.
İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.
Bu bileşiği tedarik ediyor veya sağlıyor musunuz?
Envanterinizi listeleyin veya satın alma talebi gönderin
CAS 54350-48-0
(2E,4E,6E,8E)-Butyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
Intermediates of Acitretin
(2E,4E,6E,8E)-Butyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
Pharmaceutical impurity reference standard
Acitretin Impurity 10
impurity reference standard for acitretin
(R)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-veratrylisoquinoline hydrochloride
active pharmaceutical ingredient
Triethylenephosphoramide
active pharmaceutical ingredient
Etofylline clofibrate
active pharmaceutical ingredient
5-Aminolevulinic acid hydrochloride
active pharmaceutical ingredient
ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate
HQMNCQVAMBCHCO-DJRRULDNSA-N
CCOC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C